left-arrow right-arrow pinterest facebook google_plus linkedin

Lung Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


AbbVie M19-700

Status: Suspended | Phase IB

Official Title: A Phase 1B Study Of Venetoclax In Combination With Pembrolizumab In Subjects With Previously Untreated Non-Small Cell Lung Cancer Whose Tumors Have High PD-L1 Expression

Study Purpose: To determine the safe and tolerable dose of venetoclax in combination with pembrolizumab. Learn more.


Alliance A081105

Status: Suspended | Phase III

Official Title: Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Study Purpose: To determine if it is beneficial or not to add an investigational drug, erlotinib, following the standard chemotherapy for subjects with early stage non-small cell lung cancer that has been surgically removed. Learn more


Alliance A081801

Status: Recruiting | Phase III 

Official Title: Testing The Addition Of A Type Of Drug Called Immunotherapy To The Usual Chemotherapy Treatment For Non-Small Cell Lung Cancer.

Study Purpose: To compare the usual treatment alone to using pembrolizumab plus the usual treatment. Learn more.


Alliance A151216

Status: Recruiting | Phase III 

Official Title: Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Study Purpose: To study the genes of tumor cells to determine if these results will help physicians select the best treatment options for subjects with genetic changes. Learn more.


AstraZeneca D4194C00008

Status: Recruiting | Phase III

Official Title: Prospective, Interventional Pilot Study Of Mobile Devices And Digital Applications To Detect Early Pneumonitis And Other Pulmonary Adverse Events In Unresectable Stage Iii Non-Small Cell Lung Cancer Patients On Durvalumab

Study Purpose: To test new technology that monitors your respiratory function data, oxygen saturation levels, vital signs, and physical movement data without affecting your daily life in a significant way. Learn more.


Biodesix, Inc. BDX-00146

Status: Recruiting | Phase: Not Applicable

Official Title: An observational study assessing the clinical effectiveness of the VeriStrat test and validation immunotherapy tests in subjects with non-small cell lung cancer

Study Purpose: To collect information about how your study doctor uses the results of the VeriStrat blood test to choose treatment for your NSCLC. Learn more


Calithera Biosciences CX-839-014

Status: Recruiting | Phase II

Official Title: A Phase 2 Randomized, Multicenter, Double-Blind Study Of The Glutaminase Inhibitor Telaglenastat With Pembrolizumab And Chemotherapy Versus Placebo With Pembrolizumab And Chemotherapy In First-Line, Metastatic KEAP1/NRF2-Mutated, Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)

Study Purpose: To determine the amount of telaglenastat that is safe and tolerable when given together with the recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed and to determine if the combination of standard drugs with telaglenastat is more active against your type of cancer than the standard drugs alone. Learn more. 


CTSU E4512

Status: Recruiting | Phase III

Official Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Study Purpose: To determine if patients with early stage non-small cell lung cance an investigational drug, crizotinib, following the standard chemotherapy for subjects with early stage non-small cell lung cancer that has been surgically removed. Learn more


CTSU LungMAP

Status: Recruiting | Phase II/III

Official Title: Targeted Treatment for Advanced Non-small Cell Lung Cancer

Study Purpose: The overall purpose of this study to find out if a targeted or immunotherapy treatment will have an effect on specific genes and proteins in your tumor. Learn more


CTSU S1827

Status: Recruiting | Phase III

Official Title: Testing Whether the Of Brain Scans Alone Instead Of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer

Study Purpose: To see if the use of brain scans alone instead of brain scans plus preventive brain radiation affect the lifespan of patients with small cell lung cancer. Learn more


ECOG-ACRIN EA5162

Status: Suspended | Phase II

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions. Learn more.


ECOG-ACRIN EA5163

Status: Recruiting | Phase III 

Official Title: A randomized, phase III study of firstline immunotherapy alone or in combination with chemotherapy in induction/maintenance or postprogression in advanced nonsquamous non-small cell lung cancer (NSCLC) with immunobiomarker SIGNature-driven analysis

Study Purpose: To find out whether either of these two usual approaches to treating your type of cancer is better or worse than the other. Learn more


ECOG-ACRIN EA5181

Status: Recruiting | Phase III

Official Title: Testing The Addition Of An Antibody To Standard Chemoradiation Followed By The Antibody For One Year To Standard Chemoradiation Followed By One Year Of The Antibody In Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Study Purpose: To see if we can extend your life and/or prevent your tumor from coming back by adding a study drug durvalumab during chemotherapy and radiation therapy. Learn more.


ECOG-ACRIN EA5191

Status: Recruiting | Phase II

Official Title: Testing the Addition of the Pill Chemotherapy, Cabozantinib, To the Standard Immune Therapy Nivolumab Compared To Standard Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer

Study Purpose: To compare the two investigational treatments (cabozantinib alone to using cabozantinib plus the usual treatment nivolumab) to the current standard of care second line therapy. Learn more.


Genentech GO40241

Status: Recruiting | Phase III

Official Title: A Phase III, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer

Study Purpose: To evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab in combination with platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in patients with resectable non-small cell lung cancer. Learn more


NRG LU003

Status: Recruiting | Phase III

Official Title: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-Squamous Non-Small Cell Lung Cancer

Study Purpose: This study has a screening part and a treatment part. The purpose of this initial screening is to test your tumor to find out if it has a specific mutation. The purpose of the treatment part of the study is to learn if a gene mutation is helpful to decide which different ALK targeting drug to give you compared to the usual treatment of chemotherapy and/or another ALK inhibitor not based on gene mutations. Learn more


NRG-LU005

Status: Recruiting | Phase II/III 

Official Title: Limited stage small cell lung cancer (LS-SCLC): A Phase II/III randomized study of chemoradiation versus chemoradiation plus atezolizumab

Study Purpose: Compare progression free survival and overall survival for patients with LS-SCLC treated with chemoradiation +/- atezolizumab.  Learn more


PACIFIC-4/RTOG-3515

Status: Recruiting | Phase III 

Official Title: A phase III, randomized, placebo-controlled, double-blind, multi-center, international study of durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of patients with unresected stage I/II, lymph-node negative non-small cell lung cancer

Study Purpose: The reason for the study is to find out more effective treatment for stage I/II NSCLC following stereotactic body radiation therapy, which is a standard treatment for patients with your condition. Learn more


Mirati MRT516-005

Status: Recruiting | Phase III 

Official Title: A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On Or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Study Purpose: To compare the effectiveness of sitravatinib in combination with nivolumab versus docetaxel with non-small cell lung cancer. Learn more


SWOG S1900A

Status: Suspended | Phase II

Official Title: Targeted Treatment For Advanced Non-Small Cell Lung Cancer

Study Purpose: To determine if the study drug, rucaparib can lower the chance of lung cancer growing or spreading. Learn more. 


SWOG S1929

Status: Recruiting | Phase II

Official Title: Testing Maintenance Therapy For Small Cell Lung Cancer In Patients With SLFN11 Positive Biomarker

Study Purpose: To compare the usual treatment (atezolizumab) alone to using talazoparib plus the usual treatment. Learn more